Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population

British Journal of Clinical Pharmacology

Volumn 46, Issue 5, 1998, Pages 499-504

  Hoskins, Janelle M ^a   Shenfield, Gillian M ^a   Gross, Annette S ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

CYP2C19; Gene dose effect; Genotype; Metabolic ratio; Proguanil

Indexed keywords

CYCLOGUANIL; CYTOCHROME P450; PROGUANIL;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG METABOLISM; DRUG OXIDATION; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENOTYPE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC RATE; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; URINALYSIS;

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; CHLOROGUANIDE; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MUTATION; STATISTICS; TRIAZINES;

EID: 0031787036     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00807.x     Document Type: Article

References (37)

1. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterisation of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1994; 306: 240-245.
2. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroyxlase in humans. Biochemistry 1994; 33: 1743-1752.
3. Wilkinson GR, Guengench FP, Branch RA. Genetic polymorphisin of S-mephenytoin hydroxylation, Pharmacol Ther 1989; 43: 53-76.
4. Daniel HI, Edeki TI. Genetic polymorphism of S-mephenytoin 4′-hydroxylation, Psychopharmacol Bull 1997; 32: 219-230.
5. Meehan RR, Gosden JR, Rout D, et al. Human cytochrome P-450 PB-1: A multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. Am J Hum Genet 1989; 42: 26-37.
6. Daly AK, Brockmoller J, Broly F, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201.
7. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-15422.
8. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-598.
9. Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997; 281: 604-609.
10. Ferguson RJ, de Morais SMF, Benhamou S, et al. A new genetic defect in human CYP2C19: Mutation in the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998; 284: 356-361.
11. Chang M, Dahl ML, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-363.
12. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin Pharmacol Ther 1995; 57: 662-669.
13. Brockmöller J, Rost KL, Gross D, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G→A-splice site mutation. Pharmacogenetics 1995; 5: 80-88.
14. Ward SA, Helsby NA, Skjelbo E, Brøsen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991; 31: 689-692.
15. Brøsen K, Skjelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993; 36: 105-108.
16. Wanwimolruk S, Thou MR, Woods DJ. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population. Br J Clin Pharmacol 1995; 40: 166-169.
17. Wanwimolruk S, Pratt EL, Denton JR, Chalcroft SCW, Barron PA, Broughton JR. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population. Pharmacogenetics 1995; 5: 193-198.
18. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994; 37: 413-420.
19. Funck-Brentano C, Becquemont L, Leneveu A, Roux A, Jaillon P, Beaune P. Inhibition by omeprazole of proguanil metabolism: Mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 1997; 280: 730-738.
20. Kinirons MT, O'Shea D, Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993; 54: 621-629.
21. Funck-Brentano C, Bosco O, Jacqz-Aigrain E, Keundjian A, Jaillon P. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. Clin Pharmacol Ther 1992; 51: 507-512.
22. Partovian C, Jacqz-Aigrain E, Keundjian A, Jaillon P, Funck-Brentano C. Comparison of chlorguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. Clin Pharmacol Ther 1995; 58: 257-263.
23. Coller JK, Somogyi AA, Bochner F. Association between CYP2C19 genotype and proguanil oxidative polymorphism. Br J Clin Pharmacol 1997; 43: 659-660.
24. Foster DJR, Somogyi AA, Gross AS, Bochner F. Dextromethorphan, proguanil and caffeine as phenotyping probes for polymorphism's in drug metabolism. Proc Aust Soc Clin Exp Pharmacol Toxicol 1994; 1: 43.
25. Hoskins JM, Shenfield GM, Gross AS. Modified high performance liquid chromatographic method to measure both dextromethorphan and proguanil for oxidative phenotyping. J Chromatogr 1997; 696: 81-87.
26. de Morais SMF, Goldstein JA, Xie HG, et al. Genetic analysis of the S-mephenytoin polymorphism in Chinese population. Clin Pharmacol Ther 1995; 58: 404-411.
27. Nei M. In Molecular Evolutionary Genetics. New York: Columbia University Press, 1987.
28. Edeki TI, Goldstein JA, de Morais SMF, et al. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics 1996; 6: 357-360.
29. 2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996; 59: 647-653.
30. Zhou HH, Anthony LB, Wood AJJ, Wilkmson GR. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990; 30: 471-475.
31. Jurima M, Inaba T, Kalow W. Mephenytoin hydroxylase activity in human liver: inhibition by steroids. Drug Metab Dispos 1985; 13: 746-749.
32. Walle T, Fagan TC, Walle UK, Topmiller MJ. Stimulatory as well as inhibitory effects of ethinylestradiol on the metabolic clearances of propranolol in young women. Br J Clin Pharmacol 1996; 41: 305-309.
33. Abernethy DR, Greenblatt DJ, Divoll M, Arendt R. Impairment of diazepam clearance with low-dose oral contraceptive steroid therapy. Clin Pharmacol Ther 1984; 35: 360-366.
34. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther 1984; 35: 792-797.
35. Wangboonskul J, White NJ, Nosten F, ter Kuile F, Moody RR, Taylor RB. Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. Eur J Clin Pharmacol 1993; 44: 247-251.
36. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 1990; 30: 593-598.
37. Hussein Z, Eaves CJ, Hutchinson DB, Canfield CJ. Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. Br J Clin Pharmacol 1996; 42: 589-597.